Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 5, 2012, Pages 609-621

  Chen, K W ^a   Focke Tejkl, M ^a   Blatt, K ^a   Kneidinger, M ^a   Gieras, A ^a   Dall'Antonia, F ^b   Fae I ^a   Fischer, G ^a   Keller, W ^b   Valent, P ^a   Valenta, R ^a   Vrtala, Susanne ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Der p 2; House dust mite allergy; Immunotherapy; Peptides

Indexed keywords

ALLERGEN; CYTOKINE; DER P 2 PEPTIDE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC REACTION; ALLERGY; ARTICLE; BASOPHIL; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BINDING; T LYMPHOCYTE ACTIVATION;

ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY SPECIFICITY; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; BASOPHILS; CYTOKINES; FEMALE; HEMOCYANIN; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BINDING; PYROGLYPHIDAE; PYROPHOSPHATASES; RABBITS; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 84862776765     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2012.02794.x     Document Type: Article

References (35)

1. Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002;129:1-18. (Pubitemid 35316844)
2. Ichikawa S, Takai T, Inoue T, Yuuki T, Okumura Y, Ogura K et al. NMR study on the major mite allergen Der f 2: its refined tertiary structure, epitopes for monoclonal antibodies and characteristics shared by ML protein group members. J Biochem (Tokyo) 2005;137:255-263. (Pubitemid 40628431)
3. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. Mol Immunol 1996;33:399-405. (Pubitemid 26191484)
4. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997;15:754-758.
5. Korematsu S, Tanaka Y, Hosoi S, Koyanagi S, Yokota T, Mikami B et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 2000;165:2895-2902. (Pubitemid 30660742)
6. Takai T, Mori A, Yuuki T, Okudaira H, Okumura Y. Non-anaphylactic combination of partially deleted fragments of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Mol Immunol 1999;36:1055-1065. (Pubitemid 30078908)
7. Chen K, Fuchs G, Sonneck K, Gieras A, Swoboda I, Douladiris N et al. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol Immunol 2008;45:2486-2498.
8. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(Suppl 2):14677-14682. (Pubitemid 39346742)
9. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, Suck R et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38:1514-1525.
10. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885-1894. (Pubitemid 29295887)
11. Campana R, Mothes N, Rauter I, Vrtala S, Reininger R, Focke-Tejkl M et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008;121:528-530 e1.
12. Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603. (Pubitemid 38534892)
13. Jahn-Schmid B, Fischer GF, Bohle B, Fae I, Gadermaier G, Dedic A et al. Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01. J Allergy Clin Immunol 2005;115:399-404. (Pubitemid 40215110)
14. Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J 2001;15:2042-2044.
15. Sanner MF, Olson AJ, Spehner JC. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996;38:305-320.
16. Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011;29:2140-2148.
17. Swoboda I, Bugajska-Schretter A, Verdino P, Keller W, Sperr WR, Valent P et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: a tool for diagnosis and therapy of fish allergy. J Immunol 2002;168:4576-4584. (Pubitemid 34441363)
18. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110:102-109. (Pubitemid 36132735)
19. Derewenda U, Li J, Derewenda Z, Dauter Z, Mueller GA, Rule GS et al. The crystal structure of a major dust mite allergen Der p 2, and its biological implications. J Mol Biol 2002;318:189-197. (Pubitemid 34729395)
20. Lynch NR, Thomas WR, Garcia NM, Di Prisco MC, Puccio FA, L'Opez RI et al. Biological activity of recombinant Der p 2, Der p 5 and Der p 7 allergens of the house-dust mite Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 1997;114:59-67. (Pubitemid 27338465)
21. Takai T, Yuuki T, Okumura Y, Mori A, Okudaira H. Determination of the N- and C-terminal sequences required to bind human IgE of the major house dust mite allergen Der f 2 and epitope mapping for monoclonal antibodies. Mol Immunol 1997;34:255-261. (Pubitemid 27293740)
22. Focke M, Swoboda I, Marth K, Valenta R. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010;40:385-397.
23. Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009;182:6298-6306.
24. Nakazawa T, Takai T, Hatanaka H, Mizuuchi E, Nagamune T, Okumura K et al. Multiple-mutation at a potential ligand-binding region decreased allergenicity of a mite allergen Der f 2 without disrupting global structure. FEBS Lett 2005;579:1988-1994. (Pubitemid 40404042)
25. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734 -1739.
26. Reisinger J, Triendl A, Kuchler E, Bohle B, Krauth MT, Rauter I et al. IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J Allergy Clin Immunol 2005;115:973-981. (Pubitemid 40616211)
27. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, Konig F et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347-354. (Pubitemid 41096542)
28. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008;122:951-960.
29. Paul WE, Katz DH, Goidl EA, Benacerraf B. Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med 1970;132:283-299.
30. Niespodziana K, Focke-Tejkl M, Linhart B, Civaj V, Blatt K, Valent P et al. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 2011;127:1562-1570 e6.
31. Twaroch TE, Focke M, Civaj V, Weber M, Balic N, Mari A et al. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol 2011;128:178-184 e7.
32. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445-1455. (Pubitemid 44511559)
33. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-2952. (Pubitemid 29399227)
34. van Neerven RJ, Knol EF, Ejrnaes A, Wurtzen PA. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy. Int Arch Allergy Immunol 2006;141:119-129. (Pubitemid 44413287)
35. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-922. (Pubitemid 37412059)